Sector News

Indian scientists explore 3D printing tech to enhance the efficacy of nutritional supplements

June 11, 2022
Life sciences

Scientists from the Indian Institute of Food Processing Technology (IIFPT) are using 3D printing technology to transport resveratrol and curcumin around the human body as they are difficult for the body to absorb.

The researchers have now explored using a 3D printed beeswax-based medium-chain triglycerides (MCT) oleogel as a co-delivery carrier for the nutrients.

Resveratrol and curcumin are known as nutraceuticals, a form of dietary supplement claiming to have health benefits.

According to the researchers, the combination of these two compounds is “well-studied and widely considered a synergistic health booster.”

Unfortunately, resveratrol and curcumin have low water solubility and processability makes it difficult to package them into ingestible formulations for human absorption.

Testing samples
To create a stable emulsion formulation, the researchers added varying amounts of gelatin and gellan gum to an MCT oleogel and tested the results.

They also added potato starch and whey protein to make the beeswax-based carrier gel extrudable and then 3D printed a set of nutraceutical-dosed samples with it.

It was discovered that increasing the gellan gum content made the emulsion more stable, and it even turned out to be a critical parameter in the 3D printing process.

In-vitro experimentation revealed that 3D printed carrier systems improved curcumin bioaccessibility by 1.13 times and resveratrol bioaccessibility by 1.2 times compared to a control MCT oil sample.

This study, which is the first of its kind, deals with 3D printing of emulsion-templated oleogel containing curcumin and resveratrol for synergistic benefits in the customized structure of consumer preference.

3D printing gains traction in nutrition space
The researchers believe the study is critical to understanding insights into the 3D printing of emulsion templated oleogel as nutraceutical carriers.

Earlier this year, NutritionInsight reported that 3D printing could unlock custom textures, flavors and nutritional content in nutritional foods. Still, cost, capacity and lack of printable ingredients are holding the technology back from taking over the market.

Blendhub also partnered with Essence Food, a specialist in transforming surplus food into functional products using 3D technology.

Last October, Colorcon Ventures invested an undisclosed sum in UK-based Remedy Health, which specializes in 3D printing personalized gummy stacks.

In similar developments, Nourished previously added ADM’s postbiotic to 3D-printed gummies for personalized metabolic support.

Meanwhile, tech-backed personalized nutrition and new delivery formats continue to gain traction in the nutrition arena.

Edited by Elizabeth Green

Source: nutritioninsight.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).